GSK Adds £50m Per Year To Brexit Cost Estimates
Executive Summary
Brexit is likely to cost GSK around £50m a year in the form of customs duties and transaction and administration costs. It is one of a handful of companies to have made its cost estimates public.
You may also be interested in...
UK Pharma Execs Urged To Be More Outspoken About Brexit ‘Disaster’
Pharmaceutical executives from GSK, Sanofi and the UK generic medicines industry body giving evidence on the likely effects of Brexit on the UK life sciences sector at a recent parliamentary committee hearing were asked why they have not been more outspoken about their concerns.
Pharma Lauds Brexit ‘Breakthrough’ But Says Focus Now Must Be On Drug Regulation & Supply
The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.